JPMorgan lowered the firm’s price target on Conmed (CNMD) to $40 from $43 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD:
- Michael Matson Reiterates Hold on Conmed as Slowing Organic Growth and Margin Pressure Offset 1Q26 Beat; Price Target Raised to $35.96
- Conmed reports Q1 EPS 89c, consensus 82c
- Conmed backs FY26 EPS view of $4.30-$4.45, consensus $4.45
- CNMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Conmed assumed with an Equal Weight at Wells Fargo